Novo Nordisk rebrands to Novo, updates logo

Novo Nordisk announces a major rebrand to "Novo" and updates its corporate logo, shifting its trademark bull to look to the right. The Danish drugmaker is fighting to regain ground in the highly competitive obesity market, where Eli Lilly holds a dominant 60.9% share compared to Novo's 38.8%. Despite a successful launch of oral Wegovy, which surpassed 3 million prescriptions by June 2026, Novo's stock has dropped 15% this year, prompting a cultural overhaul and new strategic principles.

Novo Nordisk rebrand to Novo

• ▪Novo Nordisk is updating its corporate logo by shifting its trademark bull to look to the right
• ▪Novo Nordisk will retain "Novo Nordisk" as its legal corporate name despite the marketing rebrand to "Novo."
• ▪Novo Nordisk's original name dates back to the 1989 merger of two competing Danish pharmaceutical companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium
• ▪Novo Nordisk announced on September 14, 2026, that it is rebranding its name to "Novo" to increase market recognition

Eli Lilly obesity market competition

• ▪Eli Lilly has increasingly leaned on a single-name identity by dropping the word "Eli" from its marketing materials
• ▪Novo Nordisk held a 38.8% share of the obesity market in the second quarter of 2026, compared to Eli Lilly's 60.9% share, according to IQVIA data cited by Eli Lilly
• ▪Novo Nordisk shares have dropped approximately 15% in 2026 amid investor pressure and competition from Eli Lilly

Oral Wegovy launch performance

• ▪The oral version of Novo Nordisk's weight-loss drug Wegovy surpassed 3 million prescriptions as of June 2026
• ▪The oral version of Wegovy secured a head start over Eli Lilly's rival weight-loss pill, Foundayo

Corporate culture overhaul

• ▪Novo Nordisk announced a broader company rebrand focused on the phrase "Lasting Health Starts Now" to build public trust and relevance
• ▪Novo Nordisk is preparing to detail its business strategy changes during its Capital Markets Day event on September 21, 2026

New company strategy principles

• ▪Novo Nordisk's updated corporate culture is based on four principles: patient-focused innovation, raising performance for stakeholders, setting clearer priorities with simpler workflows, and maintaining patient safety and ethics
• ▪Novo Nordisk designed its new corporate principles to gain advantages in a market where more of its products have gone direct-to-consumer